Invivyd appointed Marc Elia, its Chairman of the Board, as Chief Executive Officer effective August 30, 2026. Elia receives a $750,000 annual base salary, a target bonus of 70% of base, and a one-time sign-on bonus of $500,000. He was granted an option to purchase 10,700,000 shares vesting over four years. The Board also increased its size to seven directors and appointed Ian Sheffield as an independent director. Concurrently, Ajay Royan was named Lead Independent Director. The company expects top-line data from the VYD2311 clinical studies around the end of Q3 2026, with plans to submit a Biologics License Application for its anti-COVID-19 monoclonal antibody candidate. Invivyd is a biopharmaceutical company developing monoclonal antibodies for viral infectious diseases.

Invivyd reported second quarter 2026 financial results with PEMGARDA net product revenue of $14.3 million, a 21% increase from the prior year period. The company posted a net loss of $44.4 million and ended the quarter with $160.1 million in cash and cash equivalents. R&D expenses rose to $29.4 million due to clinical trial costs for VYD2311, while SG&A increased to $29.5 million. Invivyd announced that the DECLARATION pivotal clinical trial enrollment is complete and top-line data is expected later in Q3 2026. Additionally, the LIBERTY study is fully dosed with results anticipated in late Q3 2026. The company also disclosed receipt of twelve months' advance notice regarding the potential termination of PEMGARDA's emergency use authorization effective June 29, 2027. Invivyd operates as a biopharmaceutical company developing monoclonal antibodies for viral infectious diseases.

Invivyd, Inc. received a deficiency letter from Nasdaq on July 23, 2026, notifying the company that its common stock closed below the $1.00 minimum bid price requirement for 30 consecutive business days. The company has until January 19, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for ten consecutive business days. Failure to meet this requirement may lead to a potential transfer to the Nasdaq Capital Market or delisting from the exchange. Invivyd intends to monitor its stock price and consider options to resolve the deficiency. Invivyd, Inc. is a biotechnology company.

Invivyd, Inc. announced it received a twelve-month advanced notice regarding the termination of the Emergency Use Authorization (EUA) for its product PEMGARDA®. The company is currently coordinating next steps with the U.S. Food and Drug Administration (FDA) following this notification. Invivyd, Inc. is a biotechnology company focused on developing therapies for infectious diseases.